WO2008151749A3 - Aktivierbare diagnostische und therapeutische verbindung - Google Patents

Aktivierbare diagnostische und therapeutische verbindung Download PDF

Info

Publication number
WO2008151749A3
WO2008151749A3 PCT/EP2008/004481 EP2008004481W WO2008151749A3 WO 2008151749 A3 WO2008151749 A3 WO 2008151749A3 EP 2008004481 W EP2008004481 W EP 2008004481W WO 2008151749 A3 WO2008151749 A3 WO 2008151749A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnostic
activatable
therapeutic compound
compound
therapeutic
Prior art date
Application number
PCT/EP2008/004481
Other languages
English (en)
French (fr)
Other versions
WO2008151749A2 (de
Inventor
Stefan Heckl
Original Assignee
Univ Eberhard Karls
Stefan Heckl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Eberhard Karls, Stefan Heckl filed Critical Univ Eberhard Karls
Priority to EP08759034A priority Critical patent/EP2167139A2/de
Publication of WO2008151749A2 publication Critical patent/WO2008151749A2/de
Publication of WO2008151749A3 publication Critical patent/WO2008151749A3/de
Priority to US12/634,972 priority patent/US20100267928A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Verbindung, die als Kontrastmittel sowie als therapeutisches Agens eingesetzt werden kann, die Verwendung der Verbindung zur Herstellung einer diagnostischen oder therapeutischen Zusammensetzung, eine diagnostische und therapeutische Zusammensetzung, die die Verbindung aufweist sowie ein Verfahren zur diagnostischen und therapeutischen Behandlung eines Lebewesens.
PCT/EP2008/004481 2007-06-12 2008-06-05 Aktivierbare diagnostische und therapeutische verbindung WO2008151749A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08759034A EP2167139A2 (de) 2007-06-12 2008-06-05 Aktivierbare diagnostische und therapeutische verbindung
US12/634,972 US20100267928A1 (en) 2007-06-12 2009-12-10 Activatable diagnostic and therapeutic compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028090.6 2007-06-12
DE102007028090A DE102007028090A1 (de) 2007-06-12 2007-06-12 Aktivierbare diagnostische und therapeutische Verbindung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/634,972 Continuation US20100267928A1 (en) 2007-06-12 2009-12-10 Activatable diagnostic and therapeutic compound

Publications (2)

Publication Number Publication Date
WO2008151749A2 WO2008151749A2 (de) 2008-12-18
WO2008151749A3 true WO2008151749A3 (de) 2009-06-11

Family

ID=39720245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004481 WO2008151749A2 (de) 2007-06-12 2008-06-05 Aktivierbare diagnostische und therapeutische verbindung

Country Status (4)

Country Link
US (1) US20100267928A1 (de)
EP (1) EP2167139A2 (de)
DE (1) DE102007028090A1 (de)
WO (1) WO2008151749A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2233485A1 (de) * 2009-03-23 2010-09-29 Universität Regensburg Fluorphor-enthaltende Verbindungen und deren Verwendung in der Detektion von phosphorylierten (Poly)peptiden
DE102010005880B4 (de) * 2010-01-27 2016-06-23 Siemens Healthcare Diagnostics Products Gmbh Kontrastmittel und Verfahren zum Nachweis von Proteaseaktivität mittels Hyperpolarisation
GB201102189D0 (en) * 2011-02-08 2011-03-23 King S College London Materials and methods relating to cardiovascular imaging
EP3390624A4 (de) * 2015-12-18 2019-07-10 The Regents of The University of California Auf modifizierte stellen gerichtete, modifizierende polypeptide und verfahren zur verwendung davon
CN105753941B (zh) * 2016-04-26 2019-04-09 中国石油大学(华东) 一种自组装抗菌肽
CN107794280B (zh) * 2017-09-26 2022-02-11 天津大学 靶向穿膜肽基因载体及其应用
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
CA3121200A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
SG11202112054WA (en) 2019-05-03 2021-11-29 Cellphire Inc Materials and methods for producing blood products
CA3150936A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
US20210189341A1 (en) * 2019-11-27 2021-06-24 Cellphire, Inc. Platelet diagnostic imaging agents
CA3170198A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
CN115960936A (zh) * 2022-10-18 2023-04-14 湖北大学 一种智能工程细菌系统及其制备和在抗肿瘤药物中的应用
CN117731616A (zh) * 2023-12-18 2024-03-22 中山大学孙逸仙纪念医院 一种负载肿瘤抑制基因siRNA的谷胱甘肽响应纳米材料

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005096789A2 (en) * 2004-04-12 2005-10-20 Georgia Tech Research Corporation Methods and compositions for imaging and biomedical applications
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
WO2006125134A1 (en) * 2005-05-19 2006-11-23 The Regents Of The University Of California Peptides whose uptake by cells is controllable

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202635A3 (en) 1999-07-29 2006-03-28 Epix Medical Inc Cambridge Targeting multimeric imaging agents through multilocus binding
EP1424343A1 (de) 2002-11-29 2004-06-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptidkonjugat zur molekularen Zellkernabbildung oder Tumorbehandlung
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005096789A2 (en) * 2004-04-12 2005-10-20 Georgia Tech Research Corporation Methods and compositions for imaging and biomedical applications
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
WO2006125134A1 (en) * 2005-05-19 2006-11-23 The Regents Of The University Of California Peptides whose uptake by cells is controllable

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IWAKI O. ET AL.: "An NMR Study of a Poly(glutamic acid) Metal Complex", POLYMER JOURNAL, vol. 4, no. 6, 1973, pages 623 - 627, XP008104417 *

Also Published As

Publication number Publication date
EP2167139A2 (de) 2010-03-31
WO2008151749A2 (de) 2008-12-18
US20100267928A1 (en) 2010-10-21
DE102007028090A1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2008151749A3 (de) Aktivierbare diagnostische und therapeutische verbindung
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
EP2212440A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von adenokarzinomen der speiseröhre
WO2010120368A3 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
EP2349279A4 (de) Aldehyddehydrogenase-modulatoren und anwendungsverfahren dafür
WO2009019294A3 (en) Bupropion hydrobromide and therapeutic applications
WO2011159840A3 (en) Phenylthioacetate compounds, compositions and methods of use
WO2008075192A3 (en) Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
WO2009022077A3 (fr) Utilisation d'hespéridine ou de l'un de ses dérivés pour la prévention et/ou le traitement des peaux relâchées
WO2006128041A3 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
ME02017B (me) Jedinjenja, kompozicije i postupci za tretman beta-amiloidnih bolesti i sinukleinopatija
WO2008020765A3 (en) Imaging medium comprising lactate and hyperpolarised 13c-pyruvate
WO2004004636A3 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
EP2329007A4 (de) Verfahren zur stärkung der immunogenität von mykobakterien und zusammensetzungen für die behandlung von krebs, tuberkulose und fibrosierenden lungenerkrankungen
WO2007062380A3 (en) Modulation of eif4e-bp2 expression
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759034

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008759034

Country of ref document: EP